Inflammatix Inc. received U.S. FDA breakthrough device designation for its Triverity acute infection and sepsis test system, which produces three readouts that could help emergency physicians quickly determine the proper course of treatment.
Inflammatix Inc. raised $102 million in series D financing to advance development and commercialization of its novel immune response diagnostics portfolio. D1 Capital Partners led the round, with additional funds provided by existing investors Northpond Ventures LLC, Khosla Ventures, Think.Health GmbH, and OSF Healthcare Ventures, among others.